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In the last decade, it has become apparent that toll-like receptor (TLR) signaling can play an
important role in ovarian cancer (OC) progression. Interestingly, TLR activation in immune
cells can help activate an anti-tumor response, while TLR signaling in tumor cells them-
selves is often associated with cancer-promoting inflammation. For example, it has been
shown that TLR activation in dendritic cells can result in more effective antigen presenta-
tion toT cells, thereby favoring tumor eradication. However, aberrantTLR expression in OC
cells is associated with more aggressive disease (likely due to recruitment of pro-tumoral
leukocytes to the tumor site) and has also been implicated in resistance to mainstream
chemotherapy. The delicate balance of TLR activation in the tumor microenvironment in
different cell types altogether help shape the inflammatory profile and outcome of tumor
growth or regression. With further studies, specific activation or repression of TLRs may
be harnessed to offer novel immunotherapies or adjuvants to traditional chemotherapy
for some OC patients. Herewith, we review recent literature on basic and translational
research concerning therapeutic targeting of TLR pathways for the treatment of OC.
Keywords: ovarian cancer, toll-like receptors, tumor microenvironment, immunotherapy, pattern-recognition
receptors
INTRODUCTION
Ovarian cancer (OC) has the most devastating death rate of gyne-
cological cancers with only 44% of women surviving 5 years after
diagnosis (1–4). The low long-term survival statistics are in part
due to lack of efficient screening technology; by the time symp-
toms occur, most patients exhibit advanced-stage disease (over
60% of OC is diagnosed after distant metastasis). The survival rates
decrease with each later stage of diagnosis with only a 27% 5-year
relative survival rate for distantly metastasized tumors, highlight-
ing the need for more efficacious treatments for advanced OC
(4). Today, the standard of therapy includes surgery (hysterec-
tomy and bilateral salpingooophorectomy) and several rounds of
platinum- or taxane-based chemotherapy (1–3). Chemotherapy
typically produces significant side effects, such as nausea, weight
loss, fatigue, and alopecia, largely a result of toxicity of the treat-
ment to healthy cells (5). Moreover, many cancers become resistant
to treatment, further warranting the development of additional
and more tumor-specific therapies. Thus, although chemotherapy
remains the gold-standard of OC management, replacement as
well as adjuvant treatments are in process of intensive investiga-
tion. As it is well-established that the immune system (if properly
functioning) can fight tumor growth, tumor immunology research
and immunotherapy clinical trials are taking center-stage in the
quest for better clinical outcomes for late-staged OC (6–9).
As aggressive OC often correlates with an immunosuppressive
leukocyte population in the tumor environment, efforts to mod-
ulate these cells to potentiate an anti-tumor immune response are
ongoing (10–12). Of particular interest to the processes of tumor-
infiltration by immune cells and their activation are the toll-like
receptors (TLRs), pattern-recognition receptors (PRRs) that lig-
ate conserved pathogen-associated molecular patterns (PAMPs)
such as bacterial lipopolysaccharide (LPS) or viral dsRNA (13–
20). TLR expression is well-established in immune cells, such as
macrophages and dendritic cells (DCs), where upon PAMP recog-
nition, an inflammatory response occurs, activating numerous
transcription factors, such as NF-kB and IRF 3/7 (21–23). Cytokine
and chemokine secretion subsequently ensues, further activating
inflammation and stimulating the adaptive immune response. In
fact, TLR activation in leukocytes (e.g., DCs) can trigger a shift in
the inflammatory profile of the tumor site by decreasing immuno-
suppression and activating immune cells that can actively fight
tumors (11, 24, 25). However, in addition to their expression in
leukocytes, TLRs are found in multiple tumor types, including in
OC, where their activation can have tumor-promoting effects (26–
29). In fact, high levels of different TLRs in cancer cells have been
associated with disease aggressiveness, treatment resistance, and
poor clinical outcome. Most likely, this is a result of cytokine and
chemokine-induced (e.g., as a result of NF-κB activation) recruit-
ment of immunosuppressive and pro-angiogenic leukocytes to
the tumor site (13, 30–32). In this mini review, we summarize
recent studies and clinical trials aimed at exploiting TLR signaling
pathways for OC immunotherapy.
TOLL-LIKE RECEPTOR SIGNALING IN LEUKOCYTES
Toll-like receptors expressed in leukocytes (e.g., macrophages)
serve a crucial function at the start of the immune response,
activating numerous pro-inflammatory pathways resulting in
cytokine secretion, and further activation of immune cells,
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including the adaptive immune response (21–23). It is known that
the white blood cell population infiltrating the tumor environ-
ment differs between cancers and it has been established that the
specific leukocyte profile at the site has a profound effect on tumor
progression or regression (8, 30, 33). As the microenvironment of
OC is typically immunosuppressive, efforts are ongoing to stim-
ulate the immune population to effectively recognize and clear
the tumor cells (12). In this regard, TLR activation in immune
cells can favor the anti-tumor immune response, by increasing
the capability of professional antigen-presenting cells (APCs) and
facilitating the activation of anti-tumoral T cells (natural killer, NK
cells; cytotoxic T lymphocytes, CTLs). In fact, the last decade of
cancer immunology research has brought about several examples
of the benefits of TLR activation in the immune cells surrounding
the ovarian tumor milieu. Several clinical trials have been per-
formed in an attempt to stimulate TLRs for OC therapy, including
using TLR agonists in combination with other immunostimulat-
ing agents, such as DC vaccines (34, 35). Overall, these studies
point to the potentially promising effects of TLR stimulation for
OC patients with few efficacious treatment options available, espe-
cially if integrated with mainstream treatments or as adjuvants to
other immunotherapies on a case-by-case basis.
In 2005, Adams et al. first described the rationale for TLR3 ago-
nist therapy for advanced OC (35). In 2009, it was reported that
TLR3 activation in DCs enhanced antigen processing and pre-
sentation by the APCs (24). Specifically, the authors described
the inability of tumor-localized DCs to successfully activate
anti-tumor immunity. Instead, they suppressed T cell function,
although they were shown to be capable of processing tumor
antigens. However, after stimulation with dsRNA (TLR3 ligand),
with co-stimulation of CD40, DC function improved to trigger
the desired tumor-eliminating inflammatory response. In these
studies, this was indicated by the increase of interleukin 12 (IL-
12) and type I IFN secretion by the DCs, as well as higher levels
of co-stimulatory molecule expression and enhanced antigen-
processing capability in both mouse and human OC samples.
Furthermore, the treatment augmented the migratory capabili-
ties of the DCs (to lymph nodes) and increased their antigen-
presentation capability. These results point to the promising
potential to re-structure the immunosuppressive OC environment
to facilitate a robust anti-tumor response.
Earlier this year, Bellora and colleagues demonstrated that TLR
activation in tumor-associated macrophages (TAMs) obtained
from OC patients resulted in a shift from an M2 to an M1-
polarization phenotype (36). This is significant, as M2-activated
macrophages in the tumor environment are implicated in can-
cer growth, whereas M1-type (classically activated) macrophages
are associated with better clinical outcome (37). M1-polarization
is primarily immunostimulatory, characterized by the secretion
of IL-12 and production of cytotoxic factors, such as nitric
oxide (NO). M2-type or alternative macrophage activation largely
results in immunosuppressive functions, and can be differenti-
ated from M1-type activation by high levels of interleukin 10
(IL-10) secretion, as well as expression of specific markers, such
as the mannose receptor (MR). In fact, the authors demon-
strated that upon M1-polarization, the macrophages were able
to induce cytolytic activity of NK cells (36). Thus, TLR activation
in TAMs may be of clinical benefit by shifting the M2-polarized,
immunosuppressive macrophages to a more immunostimulatory,
anti-tumor phenotype.
Recently, a TLR8-specific agonist, VTX-2337 (Venti-RX Phar-
maceuticals), entered Phase II clinical trials for OC patients with
chemotherapy-resistant and recurring disease (38). The Phase I
clinical trial with this agent was conducted in 2011 and was shown
to be well-tolerated while exhibiting a dose-dependent therapeu-
tic activity (39). The rationale for the therapy is to activate TLR8
in immune cells, whereby its signaling has been shown to have
a suppressive effect on Tregs (40). Although the mechanism for
the TLR8-dependent inhibition of this immune cell population is
unclear, it is known to occur independently of DCs (41). In addi-
tion, TLR8 signaling appears to affect the morphology of NK cells,
increasing their IFN-γ secretion, thereby strengthening the innate
immune response (42). Furthermore, there have been implications
for the potential of TLR7 stimulation for OC treatment (41, 43). In
2010, Geller and colleagues were the first to administer a selective
small-molecule TLR7 agonist, 852A, to a small group of breast,
ovarian, and cervical cancer patients with recurrent disease (43).
Although significant side effects were observed with ~30% of those
enrolled in the study discontinuing the therapy prior to comple-
tion, the authors showed immune activation and stabilization of
disease in 2 of the 15 patients.
TLR9 ligands have similarly received interest as potential
treatments for OC, specifically in combination with other
immunomodulatory agents (44). In 2009, it was reported
that a combinational treatment of CpG oligodeoxynucleotides
(CpGODN), TLR9 ligand, and LL-37 (cathelicidin peptide)
resulted in a better therapeutic outcome in mice. The authors
demonstrated that the dual treatment increased the uptake of the
TLR9 agonist CpODN (as TLR9 is endosomal). It was shown that
the treatment increased the expansion and activation of NK cells
in the murine peritoneal space, indicating an activation of innate
immunity. Furthermore, studies assessing the potential role of the
NK cells in the tumor environment revealed that they were heavily
implicated in the observed anti-cancer effects of the therapy.
TOLL-LIKE RECEPTOR SIGNALING IN OVARIAN CANCER
CELLS
In 2009, Zhou and colleagues reported on the expression of TLRs
in human ovarian tissue samples, including both normal and neo-
plastic (benign and malignant) tissue (26). It was concluded that
TLR2, TLR3, TLR4, and TLR5 were found on the epithelium of
healthy ovary tissue. Additionally, this subset of TLRs was also
expressed in a variety of human epithelial tumors and in numer-
ous OC cell lines. The authors also found differential expression of
TLR6 and TLR8 on all the samples, as well as low levels of TLR1,
TLR7, and TLR9. It was demonstrated that the TLRs expressed
in the epithelial cells were functional and it was suggested that
their activation may constitute a mechanism by which the can-
cerous epithelial cells can manipulate inflammatory pathways to
encourage tumor growth. The last decade of research on TLRs
in tumor cells indicates that TLR activation in cancer cells gener-
ally results in increased production of cell survival and angiogenic
molecules, as well as up-regulation of T-cell-suppressive factors,
facilitating immune evasion. TLR signaling in ovarian has been
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FIGURE 1 |Toll-like receptor (TLR) activation in ovarian cancer cells and
immune cells results in differential effects on tumor progression. While
TLR engagement in immune cells may facilitate an anti-tumor inflammatory
microenvironment, their signaling pathways in tumor cells may result in
immunosuppression and resistance to chemotherapy, thereby furthering
tumor growth.
attributed with more aggressive disease, potential for metasta-
sis, and poorer end results in the clinic. Thus, specific inhibitors
of TLRs (delivered to tumor cells) may be explored as potential
therapeutic targets for some patients, especially in late-stage dis-
ease with fewer therapeutic options available (18). Recent research
highlights the detrimental effects of TLR engagement in OC cells,
indicating that inhibition of this receptor may be of benefit to the
patient if targeted specifically in the cancer cells that overexpress
the molecule.
The effects of TLR signaling in cancer cells have been exten-
sively investigated for TLR4, perhaps the best-studied PRR. In
2005, Huang and colleagues reported on its expression and activa-
tion in numerous mouse cancer cell lines (45). They determined
that TLR4 stimulation by LPS in tumor cells increased production
of numerous soluble factors, such as IL-6, and ultimately inhib-
ited the ability of CTLs to recognize and kill the cancer cells. It was
also found that LPS treatment of the murine tumor cell super-
natants impeded the proliferation of T cells and inhibited NK
cell activity. Further, the authors demonstrated that inhibition of
TLR4 signaling in tumor cells significantly increased survival in
animal studies. The menacing effects of TLR4 activation specif-
ically on human OC progression have also been reported (46).
Kelly et al. demonstrated that TLR4 is upregulated in numer-
ous ovarian epithelial tumors and that high expression correlates
with increased tumor progression and likelihood of developing
chemo-resistance to Paclitaxel. Additionally, TLR4 (and subse-
quent NF-κB) activation has been demonstrated for human ovar-
ian granulosa tumor cells (47). Thus, TLR4 inhibition in several
types of OC cells may be therapeutically beneficial in conjunction
with standard chemotherapy in an effort to decrease the likelihood
of drug resistance.
Similarly, TLR9 signaling by OC cells (as well as breast can-
cer cells) has been associated with disease aggressiveness and
poor clinical outcome (48). Berger and colleagues determined
that higher levels of TLR9 expression correlated with more severe
tumor grade. Consistently, in vitro scratch essays revealed the
increased migratory capabilities of tumor cells expressing higher
TLR9 levels (in both ovarian and breast tumor cells). It was
also reported that higher TLR9 expression was more common in
poorly differentiated tumors (hormone-receptor-negative tumor
cells were found to have more TLR9); thus, these tumors have
fewer targeted therapeutic options. In addition, it was found
that OC patients with metastatic disease had elevated levels of
hypo-methylated DNA (TLR9 ligand) in their serum. Further, the
authors offered even more evidence of the detrimental effects of
TLR9 signaling in OC cells, showing the co-localization of TLR9
and its ligand, as well as NF-κB activation, which was proportional
to the levels of TLR9 expression. Significantly, NF-κB appears to
be constitutively activated in numerous cancer types, whereby it
is associated with highly aggressive disease and poor disease out-
come, highlighting the potential of TLR targeting to inhibit this
important inflammatory switch in tumor cells (28, 49).
ENDOGENOUS TLR LIGANDS AND IMPLICATIONS FOR
CANCER THERAPY
In addition to the PAMPs that can activate TLRs (e.g., LPS, viral
RNA, etc.), endogenous ligands for these molecules have also been
identified (50). For instance, TLR2 and TLR4 can be triggered by
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biglycan and endoplasmin, while nucleic acid-sensing TLRs can
bind to mRNA (TLR3), as well as siRNA (TLR7, TLR8). Addition-
ally, damage-associated molecular patterns (DAMPs), molecules
induced during cell stress or damage (e.g., HMGB1) can acti-
vate TLRs (51–53). As discussed, attempts to harness TLRs to
promote cancer regression have been attempted in numerous
trials, where the treatments are often used in combination with
standard chemotherapy or radiation practices in an effort to max-
imize patient response. In fact, it appears likely that cell death
(e.g., necrosis from standard therapy) can result in release of
endogenous TLR ligands, which may activate nearby leukocytes,
potentially improving the anti-tumor response (50). Continued
characterization of ligands and determining downstream signaling
will help elucidate the full function of TLRs in cancer progression
and give more direction for novel therapeutic strategies for specific
cancer types.
CONCLUDING REMARKS
The last decade of research on TLR activity and its implications in
OC progression indicate that inhibition of certain TLRs in cancer
cells and/or TLR stimulation in immune cells may be of therapeu-
tic benefit in some patients. While immune activation by means of
TLR stimulation can generate an anti-cancer effect, the cytokine
profile following TLR activation in tumor cells typically favors an
immunosuppression that can potentiate immune-tolerance and
promote angiogenesis, furthering tumor growth. Figure 1 sum-
marizes the differential effects of TLR signaling by OC cells and
immune cells. Undoubtedly, TLR targeting is a promising area of
research for OC and other malignancies, although these pathways
can produce such varying effects that exploitation of TLR pathways
for cancer therapy has frequently been referred to as a “double-
edged sword” (54, 55). Therefore, TLR targeting for OC therapy
must be pursued with care and stimulating or inhibiting agents be
delivered in a cell-specific manner. Given the complex nature of
the effects of TLR activation in various cells, much remains to be
investigated, including the multiple regulators of TLR expression
and activation in the different cell types. For instance, miRNAs
have recently been shown to be “fine-tuning” regulators of TLR
signaling pathways; thus further research in this exciting area of
study may yield even more targeting opportunities for TLR reg-
ulation that could be applied in cancer therapy (56, 57). Finally,
future therapeutic strategies may be realized more effectively in
conjunction with novel drug delivery mechanisms that allow for
more cell-specific drug targeting.
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